All of the circumstances influencing any of the elements of Virchow’s Triad can increase the risk of venous thromboembolism. Assessing prothrombotic factors can sometimes be difficult. One of the examples of such a condition is nephrotic syndrome. In this condition at least two elements of Virchow’s triad are affected: physiological blood composition and the venous blood flow which is slowed down by the edema. Except for the cases mentioned in KDIGO (Kidney Disease: Improving Global Outcomes), the use of anticoagulant drugs in the prophylaxis of VTE (Venous Thromboembolism) in nephrotic syndrome seems unclear. Nevertheless, due to the increased risk of VTE, it is worth implementing mechanical anticoagulant prophylaxis, which can also improve the quality of life of patients by reducing swelling. The article analyzes the current knowledge on the field and gives some proposals with low bleeding risk.
ZakaiNAMcClureLA. Racial differences in venous thromboembolism. J Thromb Haemostasis. 2011;9:1877-1882.
2.
StoneJHanggePAlbadawiH, et al.Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017;7:S276-S284.
3.
WillanARO’BrienBJCookDJ. Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Contr Clin Trials. 1997;18:121-130.
4.
RankinAJMcQuarrieEPFoxJG, et al.Venous thromboembolism in primary nephrotic syndrome – is the risk high enough to justify prophylactic anticoagulation?Nephron. 2017;135:39-45.
5.
BellomoRWoodCWagnerI, et al.Idiopathic membranous nephropathy in an Australian population: the incidence of thromboembolism and its impact on the natural history. Nephron. 1993;63:240-241.
6.
WaldmanMCrewRJValeriA, et al.Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445-453.
7.
LinRMcDonaldGJollyTBattenAChackoB. A Systematic review of prophylactic anticoagulation in nephrotic syndrome. Kidney Int Rep. 2019 ;5:435-437.
8.
BarbourSJGreenwaldADjurdjevO, et al.Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81:190-195.
9.
MacLellanDGFletcherJP. Mechanical compression in the prophylaxis of venous thromboembolism. ANZ J Surg. 2007;77:418-423.
SutkowskaE. Usefulness of intermittent pneumatic compression in medicine. Physiotherapy. 2017;24:23-26.
12.
LiSJTuYMZhouCSZhangLHLiuZH. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol. 2016;20:212-217.
13.
FentonASmithSWHewinsP. Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC Nephrol. 2018;19:207.
14.
FahalIHMcclellandPHayCRBellGM. Arterial thrombosis in the nephrotic syndrome. Postgrad Med1994;70: 905-909.
15.
MahmoodiBKten KateMKWaandersF, et al.High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117:224-230.
16.
KumarSChapagainANitschDYaqoobMM. Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study. BMC Nephrol. 2012;13:107.
17.
MaasRJDeegensJKBeukhofJR, et al.The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a case series. Am J Kidney Dis. 2017;69:637-646.
18.
Improving Global Outcomes (KDIGO 2021) Glomerulonephritis Work Group. Clinical practice guideline for the management of glomerular diseases. .Kidney Int Suppl. 2021;100:S36.
19.
LiSJGuoJZZuoK, et al.Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study. Thromb Res. 2012;130:501-505.
20.
LionakiSDerebailVKHoganSL, et al.Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7:43-51.
21.
ZhangLJZhangZLiSJ, et al.Pulmonary embolism and renal vein thrombosis in patients with nephrotic syndrome: prospective evaluation of prevalence and risk factors with CT. Radiology. 2014;273:897-906.
22.
SinghalRBrimbleKS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118:397-407.
23.
GlassockRJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18:2221-2225.
24.
WelanderFHolmbergHDiményEJanssonUSjalanderA. Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome-A retrospective observational study. PLoS One. 2021;16:e0255009.
25.
Müller-BühlULeutgebREngeserPAchankengENSzecsenyiJLauxG. Varicose veins are a risk factor for deep venous thrombosis in general practice patients. Vasa. 2012;41:360-365.
26.
GavishIBrennerB. Air travel and the risk of thromboembolism. Intern Emerg Med. 2011;6:113-116.
IchinoseMSasagawaNChibaTToyamaKKayamoriYKangD. Protein C and protein S deficiencies may be related to survival among hemodialysis patients. BMC Nephrol. 2019; 20:191.
29.
CetinOBekpinarSUnlucerciYTurkmenABayramCUlutinT. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol. 2006;65:97-102.
30.
CiancioloGDe PascalisADi LulloLRoncoCZanniniCMannaGL. Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first. Cardiorenal Med. 2017;7:255-266.
31.
Gordon-CappitelliJChoiMJ. Prophylactic Anticoagulation in Adult Patients with Nephrotic Syndrome. Clin J Am Soc Nephrol. 2020;15:123-125.
32.
KauffmannRHVeltkampJJVan TilburgNHVan EsLA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med. 1978;65:607-613.
33.
CosioFGHarkerCBatardMABrandtJTGriffinJH. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med. 1985;106:218-222.
34.
AndersonFAJrWheelerHBGoldbergRJ, et al.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
35.
RabelinkTJZwagingaJJKoomansHASixmaJJ. Thrombosis and hemostasis in renal disease. Kidney Int. 1994;46:287-296.
36.
SchlegelN. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost. 1997;23:271-280.
37.
KayaliFNajjarRAswadFMattaFSteinPD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med. 2008;121:226-230.
38.
KerlinBAAyoobRSmoyerWE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7:513-520.
39.
HârzaMIsmailGMitroiG, et al.Histological diagnosis and risk of renal vein thrombosis, and other thrombotic complications in primitive nephrotic syndrome. Rom J Morphol Embryol. 2013;54:555-560.
40.
ZouPMLiHCaiJF, et al.A cohort study of incidences and risk factors for thromboembolic events in patients with idiopathic membranous nephropathy. Chin Med Sci J. 2018;33:91-99.
41.
LeeTDerebailVKKshirsagarAV, et al.Patients with primary membranous nephropathy are at high risk of cardiovascular events. Kidney Int. 2016;89:1111-1118.
42.
LeeTBiddleAKLionakiS, et al.Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 2014;85:1412-1420.
43.
MalyszkoJMalyszkoJSMysliwiecM. Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. Blood Coagul Fibrinolysis. 2002;13:615-621.
44.
ZhangLZhangHZhangJTianHLiangJLiuZ. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study. Exp Ther Med. 2018;15:739-744.
45.
JovenJClivilléXCampsJ, et al.Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity. Clin Chem. 1997;43:1223-1231.
46.
ColleJPMishalZLestyC, et al.Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency?Thromb Haemostasis. 1999;82:1482-1489.
47.
AbdelhafizAHMyintMPTayekJAWheeldonNM. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Therapeut. 2009;31:1534-1539.
48.
KatoSChernyavskySTokitaJE, et al.Relationship between proteinuria and venous thromboembolism. J Thromb Thrombolysis. 2010;30:281-285.
49.
MirrakhimovAEAliAMBarbaryanAPrueksaritanondSHussainN. Primary nephrotic syndrome in adults as a risk factor for pulmonary embolism: an up-to-date review of the literature. Internet J Nephrol. 2014;2014:916760-916769.
50.
WalterEDeppermannDAndrassyKKoderischJ. Platelet hyperaggregability as a consequence of the nephrotic syndrome. Thromb Res. 1981;23:473-479.
51.
RobertAOlmerMSampolJGugliottaJECasanovaP. Clinical correlation between hypercoagulability and thromboembolic phenomena. Kidney Int. 1987;31:830-835.
52.
MachleidtCMettangTStarzEWeberJRislerTKuhlmannU. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int. 1989; 36:1119-1124.
53.
WasilewskaAMZoch-ZwierzWMTomaszewskaBBiernackaA. Platelet-derived growth factor and platelet profiles in childhood nephrotic syndrome. Pediatr Nephrol. 2005;20:36-41.
54.
EnemanBLevtchenkoEvan den HeuvelBVan GeetCFresonK. Platelet abnormalities in nephrotic syndrome. Pediatr Nephrol. 2016;31:1267-1279.
55.
McGinleyELoweGDBoulton-JonesMForbesCDPrenticeCR. Blood viscosity and haemostasis in the nephrotic syndrome. Thromb Haemostasis. 1983;49:155-157.
56.
OviasuEFamoduAAOjehEA. Plasma viscosity in nephrotic Nigerians. Clin Hemorheol Microcirc. 1998;19:163-167.
57.
SahuSNageswariKBanerjeeRPuniyaniRR. Hemorheological changes in nephrotic syndrome. Clin Hemorheol Microcirc.1998;19:17-20.
58.
von GrooteTCWilliamsGAuEH, et al.Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11:CD004293.
59.
van ZaaneBNurESquizzatoA, et al.Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemostasis. 2010;8:2483-2493.
60.
MajoorCJSneeboerMMde KievitA, et al.The influence of corticosteroids on hemostasis in healthy subjects. J Thromb Haemostasis. 2016;14:716-723.
CarmonaADíaz-RicartMPalomoM, et al.Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant. 2013;19:1439-1445.
63.
WangZDangCZhuK, et al.Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients. Mol Clin Oncol. 2015;3:1088-1092.
IsmailGMircescuGDitoiuAVTacuBDJurubitaRHarzaM. Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters. Int Urol Nephrol. 2014;46:787-792.
66.
DurraniJMalikFAliNJafriSIM. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect. 2018;8:145-148.
67.
YacobiAUdallJALevyG. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther. 1976;19:552-558.
68.
PiroliRJPassanantiGTShivelyCAVesellES. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin Pharmacol Ther. 1981;30:810-816.
69.
SextonDJde FreitasDGLittleMA, et al.Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. Kidney Int Rep. 2018;3:784-793.
70.
VílchezJAGallegoPLipGY. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf. 2014;5:8-20.
71.
Medjeral-ThomasNZiajSCondonM, et al.Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol. 2014;9:478-483.
72.
HofstraJMWetzelsJFM. Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?Kidney Int. 2016;89:981-983.
73.
RibicCCrowtherM. Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology Am Soc Hematol Educ Program. 2016;2016:188-195.
74.
PrettoCRWinkelmannERHildebrandtLMBarbosaDAColetCFStummEMF. Quality of life of chronic kidney patients on hemodialysis and related factors. Rev Lat Am Enfermagem. 2020;28:e3327.
75.
EzeARComerotaAJCisekPL, et al.Intermittent calf and foot compression increases lower extremity blood flow. Am J Surg. 1996;172:130-134.
76.
DelisKTSlimaniGHafezHMNicolaidesAN. Enhancing venous outflow in the lower limb with intermittent pneumatic compression. A comparative haemodynamic analysis on the effect of foot vs. calf vs. foot and calf compression. Eur J Vasc Endovasc Surg. 2000;19:250-260.
77.
LippiGFavaloroEJCervellinG. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost. 2011;37:237-251.
78.
TessariMTisatoVRimondiEZamboniPMalagoniAM. Effects of intermittent pneumatic compression treatment on clinical outcomes and biochemical markers in patients at low mobility with lower limb edema. J Vasc Surg Venous Lymphat Disord. 2018;6:500-510.
79.
MarinovichRLiZTamasiTQuinnKWongSMcIntyreCW. Hemodynamic response to non-pneumatic anti-shock compression garments in patients with renal dysfunction. BMC Nephrol. 2020;21:15.
80.
TorresCFuentesHESaadaldinH, et al.Intermittent pneumatic compression in patients with ESRD. A systematic review. Hemodial Int. 2019;23:433-444.
